FDA Quality of Life Subcommittee
Executive Summary
FDA appoints new subcommittee to the Oncologic Drugs Advisory Committee to discuss quality of life issues. The committee will be made up of members of the Oncologic Drugs Advisory Committee as well as quality of life experts. Its first meeting is tentatively scheduled for Feb. 10